共 39 条
- [21] Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group (NCCTG).BLOOD, 2002, 100 (11) : 361A - 361AWitzig, TEVukov, AMHabermann, TMGeyer, SFriedenberg, WRWhite, WLSalim, MFlynn, PJFitch, TRMorton, RF
- [22] The addition of rituximab to frontline chop significantly improves time to treatment failure and response duration in all flipi risk groups of patients with advanced-stage follicular lymphoma: Results of a randomized trial of the german low-grade lymphoma study groupANNALS OF ONCOLOGY, 2008, 19 : 181 - 181Hoster, E.Unterhalt, M.Buske, C.Dreyling, M.Hiddemann, W.
- [23] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas:: results of a phase-II study of the German Low-Grade Lymphoma Study GroupANNALS OF HEMATOLOGY, 2000, 79 (09) : 493 - 500Feuring-Buske, MKneba, MUnterhalt, MEngert, AGramatzki, MHiller, ETrümper, LBrugger, WOstermann, HAtzpodien, JHallek, MAulitzky, EHiddemann, W
- [24] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study GroupAnnals of Hematology, 2000, 79 : 493 - 500M. Feuring-BuskeM. KnebaM. UnterhaltA. EngertM. GramatzkiE. HillerL. TrümperW. BruggerH. OstermannJ. AtzpodienM. HallekE. AulitzkyW. Hiddemann
- [25] A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyCancer Chemotherapy and Pharmacology, 2012, 69 : 835 - 843Joseph ChaoTimothy W. SynoldRobert J. MorganCharles KunosJeff LongmateHeinz-Josef LenzDean LimStephen ShibataVincent ChungRonald G. StollerChandra P. BelaniDavid R. GandaraMark McNamaraBarbara J. GitlitzDerick H. LauSuresh S. RamalingamAngela DaviesIgor Espinoza-DelgadoEdward M. NewmanYun Yen
- [26] A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 835 - 843Chao, JosephSynold, Timothy W.Morgan, Robert J., Jr.Kunos, CharlesLongmate, JeffLenz, Heinz-JosefLim, DeanShibata, StephenChung, VincentStoller, Ronald G.Belani, Chandra P.Gandara, David R.McNamara, MarkGitlitz, Barbara J.Lau, Derick H.Ramalingam, Suresh S.Davies, AngelaEspinoza-Delgado, IgorNewman, Edward M.Yen, Yun
- [28] A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remissionBONE MARROW TRANSPLANTATION, 2010, 45 : S42 - S43Tarella, C.Ladetto, M.Benedetti, F.Vitolo, U.Pulsoni, A.Patti, C.Callea, V.Rambaldi, A.Piccin, A.Devizzi, L.Musso, M.Iannitto, E.Spedini, P.Liberati, A. M.Ciceri, F.Gallamini, A.Rodeghiero, F.Gini, G.De Crescenzo, A.Di Raimondo, F.Levis, A.Chisesi, T.Petrone, T.Scalabrini, D. RotaRossi, G.Carella, A. M.Parvis, G.Majolino, I.Passera, R.Ruella, M.Pileri, A.Gianni, A. M.Corradini, P.
- [29] Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Kim, Won SeogJurczak, WojciechSancho, Juan-ManuelJavrid, EdvardKim, Jin SeokRivas, Jose Angel HernandezProkharau, AliaksandrVasilica, MarianaNagarkar, RajnishOsmanov, DzhelilBuske, ChristianKwak, LarryOgura, MichinoriLee, Sang JoonLee, Sung YoungBae, YunjuCoiffier, Bertrand
- [30] TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUPHAEMATOLOGICA, 2017, 102 : 24 - +Borchmann, P.Goergen, H.Kobe, C.Fuchs, M.Greil, R.Zijlstra, J. M.Huettmann, A.Markova, J.Meissner, J.Feuring-Buske, M.Bentz, M.Dierlamm, J.Kuehnhardt, D.Lohri, A.Novak, U.Eichenauer, D.Eich, H.Baues, C.Stein, H.Diehl, V.Kuhnert, G.Dietlein, M.Engert, A.